Abstract 2066P
Background
This study aimed to assess the usefulness of ChatGPT and Perplexity's responses to frequently asked questions regarding the diagnosis and treatment of rectal cancer.
Methods
Both artificial intelligence systems were asked 20 questions covering disease risk factors, screening, symptoms, treatment, and treatment side effects. In accordance with the ESMO patient guides, the questions were posed in the order specified. According to ESMO patient guide recommendations, responses were graded as “appropriate,” “inappropriate,” or “insufficient.”
Results
While ChatGPT provided appropriate responses to 17 of the questions (85%), the responses to two questions (10%) were deemed inappropriate, and the response to one question (5%) was deemed insufficient. Nineteen (95%) of Perplexity's responses were deemed appropriate. It was determined that both artificial intelligence systems responded improperly to the nutrition question.
Conclusions
The study's findings indicate that ChatGPT and Perplexity provide patients with accurate information about rectal cancer. The accuracy rate of Perplexity was found to be higher than that of ChatGPT. It can be demonstrated that the benefit of Perplexity is that it displays the source for each piece of information. However, especially cancer patients require emotional and psychological assistance, and further research is required to determine the impact of these artificial intelligence systems on the patient's psychology. Moreover, given the complexity and individuality of medical care, AI chatbots should not be viewed as a replacement for medical professionals, but rather as a supplement that can help patients gain access to trustworthy information and support. Overall, this study contributes to the growing body of literature on AI chatbots and their potential use in cancer by highlighting both the advantages and disadvantages of these technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06